Tests brain stimulation with mindfulness for adults with depression
Tests remotely given brain stimulation with mindfulness in 25 adults with depression.
Plain-language title generated from the registry record
Registry title: Transcranial Direct Current Stimulation for Depression
Key facts
- Where
- Woodbridge, United StatesSee the site
Where in United States
- Soterix Medical, Inc.Woodbridge, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Soterix Medical
- Trial code
- NCT07042217
- Record updated
- 19 October 2026
- Original description
This study will test the efficacy of transcranial direct current stimulation (tDCS) combined with mindfulness, remotely-delivered using a telemedicine protocol in 25 adults with unipolar depression.Read full original descriptionShow less
A Randomized, Double-blind, Parallel-arm, Sham-controlled Trial of ElectraRx Mindfulness Transcranial Direct Current Treatment System (Elect-MDS) for Adults With Major Depressive Disorder
This study will test the efficacy of transcranial direct current stimulation (tDCS) combined with mindfulness, remotely-delivered using a telemedicine protocol in 25 adults with unipolar depression.
Inclusion: Clinically stable patients that meet criteria for diagnosis of MDD according to DSM-V-TR and confirmed with the Mini International Neuropsychiatric interview; Currently experiencing a major depressive episode of at least 4 week's duration as part of a unipolar depression; QIDS-SR score >11 on all three days of screening week (Days 1,3, 7); Scored at least 17 (inclusive) on the HDRS-17 at trial entry; Any antidepressant medication is stable ≥ 30 days prior to HDRS-17 screening; Female patients are allowed if not pregnant and using a medically acceptable method of contraception, if of childbearing potential.
Exclusion: Drug or alcohol abuse or dependence in the preceding 3 months; Concurrent benzodiazepine medication; Failure to respond to ECT treatment or rTMS treatment in this or any previous episode; Failure to respond to at least 2 antidepressant medications; Current DSM-V-TR psychotic disorder; History of clinically defined neurological disorder or insult that may impact participation in this study as determined by study physician; Implanted pump, neurostimulator, cardiac pacemaker or defibrillator; High suicide risk assessed during clinician screening at baseline interview; Metal in the cranium or skull defects; Skin lesions on scalp at the proposed electrode sites; Pregnancy.